A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2002
11/05/2002	US6476038 Amino substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines
11/05/2002	US6476037 L-arginine and phosphodiesterase (PDE) inhibitor synergism
11/05/2002	US6476036 Sodium salt of 3-(4-cinnamyl-1-piperazinyl)-imino-methyl rifamycin SV
11/05/2002	US6476035 Indole and 2,3-dihydroindole derivatives, their preparation and use
11/05/2002	US6476034 Antiviral azaindole derivatives
11/05/2002	US6476033 Medicaments containing doxazosin mesylate of crystalline modification D
11/05/2002	US6476032 2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)one derivatives
11/05/2002	US6476031 Quinazoline derivatives as medicaments
11/05/2002	US6476030 Pyrazolo-triazine derivatives as ligands for GABA receptors
11/05/2002	US6476029 7-alkyl- and cycloalkyl-substituted imidazotriazinones
11/05/2002	US6476028 Compounds and methods
11/05/2002	US6476026 Compounds and compositions as protease inhibitors
11/05/2002	US6476025 Phenylphennanthridines with PDE-IV inhibiting activity
11/05/2002	US6476023 Aromatic heterocyclic compounds as anti-inflammatory agents
11/05/2002	US6476022 Oxathiepino[6,5-b]dihydropyridines, and related compositions and methods
11/05/2002	US6476020 Imidazo-benzazepine compounds, their compositions and uses
11/05/2002	US6476018 Fused imidazole derivatives as multidrug resistance modulators
11/05/2002	US6476017 (dibenzo(b,e)(1,4)-diazepine-11-yl)benzoic acid derivatives
11/05/2002	US6476016 Inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation
11/05/2002	US6476014 Chelated 8-hydroxyquinoline for the treatment of epithelial lesions
11/05/2002	US6476013 Method of chlamydia prophylaxis
11/05/2002	US6476012 For therapy of symptomology associated with menopause
11/05/2002	US6476011 Methods for introducing an estrogenic compound
11/05/2002	US6476010 Orally administering to a post-menopausal woman a fat soluble vitamin and a fat soluble vitamin absorption increasing effective amount of l-carnitine or salts
11/05/2002	US6476009 Method for control and treatment of acquired immunodeficiency syndrome (AIDS)
11/05/2002	US6476008 Use of diphosphonic acids or the physiologically acceptable salts or esters thereof in the preventive treatment of after-effects resulting from enlargement or replacement of the bladder
11/05/2002	US6476007 Isoform specific inhibition for treatment of pain and reduction of anesthetic threshold
11/05/2002	US6476006 Compact form for oral administering; bone disorders
11/05/2002	US6476005 Oral and injectable nutritional composition
11/05/2002	US6476004 Pharmaceutical composition
11/05/2002	US6476003 Method for preparing small particle size glucan in a dry material
11/05/2002	US6476002 Treatment of chronic inflammatory diseases with CM101/GBS toxin
11/05/2002	US6476001 Facilitation of repair of neural injury with CM101/GBS toxin
11/05/2002	US6476000 Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
11/05/2002	US6475998 Methods and compositions for the treatment of injury to the central nervous system
11/05/2002	US6475997 Methods of stimulating phagocytosis
11/05/2002	US6475995 Oral delivery of nucleic acid vaccines by particulate complexes
11/05/2002	US6475993 Administering aminoglycoside antibiotic; suppression of mutants
11/05/2002	US6475992 Methods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria
11/05/2002	US6475991 Use of α-alkylglucosides and α-alkylglucoside esters as anti-microbial an agents
11/05/2002	US6475990 Drugs, foods or drinks with the use of algae-derived physiologically active substances
11/05/2002	US6475985 Nucleosides with antiviral and anticancer activity
11/05/2002	US6475804 Composition and method for diagnosing auto-immune hepatitis
11/05/2002	US6475795 Use of hyaluronan in gene therapy
11/05/2002	US6475780 Alphavirus vectors for paramyxovirus vaccines
11/05/2002	US6475766 Human osteoclast-derived cathepsin
11/05/2002	US6475746 Method of obtaining a composition comprising a 5-HT1D selective compound
11/05/2002	US6475724 Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
11/05/2002	US6475718 Genetically engineered eukaryotic cell; for prevention of viral infections; viricides
11/05/2002	US6475534 Ginkgo biloba composition, method to prepare the same and uses thereof
11/05/2002	US6475531 Safe botanical drug for treatment and prevention of influenza and increasing immune function
11/05/2002	US6475530 Methods and compositions for producing weight loss
11/05/2002	US6475526 Zinc containing compositions for anti-viral use
11/05/2002	US6475524 Composition of matter
11/05/2002	US6475521 Biphasic controlled release delivery system for high solubility pharmaceuticals and method
11/05/2002	US6475520 Pharmaceutical composition with low toxicity for anti-inflammation and anti-exudation
11/05/2002	US6475518 Methods and compositions for treatment of disorders associated with chlamydia and similar bacterial infection
11/05/2002	US6475514 Athletic patch
11/05/2002	US6475512 Process for improving glucose metabolism, satiety, and nutrient absorption in companion animals
11/05/2002	US6475509 Covalent conjugates of sodium channel blockers and active compounds
11/05/2002	US6475508 Methods and pharmaceutical compositions for the closure of retinal breaks
11/05/2002	US6475507 Sustained release compositions and the process for their preparation
11/05/2002	US6475506 Infusion preparation
11/05/2002	US6475494 In an oral dosage form, providing a combination product analgesically effective when administered orally, but which is aversive in addicts at the same dose or higher dose than prescribed; prevention of drug abuse, drug dependency
11/05/2002	US6475491 Treatment of HIV and other viral infections using combinatorial therapy
11/05/2002	US6475490 Compositions and methods for promoting tissue repair using heat shock proteins
11/05/2002	US6475487 Treatment of a patient by administering an antibody that inhibits cathepsin O
11/05/2002	US6475477 Radio-opaque polymer biomaterials
11/05/2002	US6475468 Modulated release particles for aerosol delivery
11/05/2002	US6475467 Medicinal aerosol formulations
11/05/2002	US6475182 Fluidic media introduction apparatus
11/05/2002	CA2284717C Pet food composition
11/05/2002	CA2205366C Meso-monoiodo-substituted tetramacrocyclic compounds and methods for making and using the same
11/05/2002	CA2147124C Erythropoietin analogs
11/05/2002	CA2118488C 5-o-desosaminylerythronolide a derivative
11/05/2002	CA2110166C Tableting of colestipol hydrochloride
11/05/2002	CA2049811C Stabilized solid chemical compositions
11/05/2002	CA2038379C Trifluoromethyl mercaptan and mercaptoacyl derivatives and method of using same
11/05/2002	CA2038029C 1-alkyl-, 1-alkenyl- and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds, a process and intermediates for their preparation and theeir use as medicaments
11/05/2002	CA2037779C Antibiotic ge 2270 factors b1, b2, c1, c2, d1, d2, e and t
11/04/2002	WO2004001058A2 Transcription factor modulating compounds and methods of use thereof
11/04/2002	EP0904109A4 Targeting macromolecular prodrugs to t lymphocytes
11/02/2002	CA2384344A1 4-(2-pyridyl)piperizines having 5ht7 receptor agonist activity
11/01/2002	CA2384227A1 Combination treatment for anxiety and depression
11/01/2002	CA2345864A1 Androgen-mediated neuroprotection and its use for prevention, treatment and study of neural disease
10/2002
10/31/2002	WO2002086504A2 Individualization of therapy with gastroesophageal reflux disease agents
10/31/2002	WO2002086156A2 New polynucleotides and polypeptides of the ifn$g(a)-17 gene
10/31/2002	WO2002086123A2 A human g-protein coupled receptor, hgprbmy11, expressed highly in heart and variants thereof
10/31/2002	WO2002086113A2 Enzyme and snp marker for disease
10/31/2002	WO2002086105A1 Delivery of polynucleotide agents to the central nervous sysstem
10/31/2002	WO2002086090A2 Identification of essential genes of aspegillus fumigatus and methods of use
10/31/2002	WO2002086078A2 Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic agents
10/31/2002	WO2002086069A2 Secreted proteins
10/31/2002	WO2002085925A2 Melanocortin receptor ligands
10/31/2002	WO2002085910A1 Polymorph forms of n-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)-2-(2- oxopyrrolidin -1 -yl)acetamide
10/31/2002	WO2002085908A1 Folate mimetics and folate-receptor binding conjugates thereof
10/31/2002	WO2002085907A1 Novel 3-c(o)r substituted 10-cyclohexylbenzoyl pyrrolobenzodiazepines; tocolytic oxytocin receptor antagonists
10/31/2002	WO2002085906A2 Phthalazinones derivatives useful as pde4/7 inhibitors
10/31/2002	WO2002085903A2 Amyloid plaque aggregation inhibitors and diagnostic imaging agents
10/31/2002	WO2002085901A1 Substituted azabicyclic moieties for the treatment of disease (nicotinic acethylcholine receptor agonists)

1 ... 5661 5662 5663 5664 5665 5666 5667 5668 5669 5670 5671 5672 5673 5674 5675 5676 5677 5678 5679 5680 5681 ... 7860